Davion Healthcare Plc (DAVI) Stock

About Davion Healthcare Plc

Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary. It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.

Davion Healthcare Plc is headquartered in IE.

Davion Healthcare Plc (DAVI) stock trades at $6.00 with a market capitalization of $150.00M. Over the past 52 weeks the stock has ranged between $5.67 and $12.30, and currently trades 51.2% below its 52-week high.

Official website: www.davionhealthcare.com

Davion Healthcare Plc (DAVI) — frequently asked questions